CTOs on the Move

Axion Pharmaceuticals

www.jaspercapital.com

 
Axion Pharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.jaspercapital.com
  • 395 Oyster Point Blvd Ste 405
    South San Francisco, CA USA 94080
  • Phone: 650.906.4450

Executives

Name Title Contact Details

Similar Companies

HotSpot Therapeutics

HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways.

Palleon Pharmaceuticals

Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.

BioClin Therapeutics Inc

BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.

LAVA Therapeutics

At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.

Strategic Partnerships

Strategic Partnerships, LLC is a Alexandria, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.